<DOC>
	<DOCNO>NCT02394132</DOCNO>
	<brief_summary>The purpose study investigate effectiveness use either radiotherapy ( RT ) Imiquimod ( ImiQ ) treat Lentigo Maligna ( LM ) , surgery possible , refuse , fails . Surgery standard treatment people diagnose LM . However people , may possible due location LM lesion ( ) . Currently , Australian New Zealand Melanoma Treatment Guidelines recommend radiotherapy treatment LM however clinical trial evidence trial need prove treatment safer effective . Some clinician may also recommend use cream call Imiquimod . It approve widely use Australia treat solar keratosis , superficial basal cell carcinoma , external genital wart , perianal wart . Although currently license treatment use LM , evidence suggest safe effective treating LM . This trial scientifically evaluate compare two treatment control clinical setting .</brief_summary>
	<brief_title>Radiotherapy Imiquimod Complex Lentigo Maligna</brief_title>
	<detailed_description />
	<mesh_term>Lentigo</mesh_term>
	<mesh_term>Hutchinson 's Melanotic Freckle</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>1 . Aged 18 year old . 2 . A biopsyproven LM . This include previous treatment failure ( imiquimod RT ) LM diagnose biopsyproven LM . 3 . LM location amenable treatment imiquimod radiotherapy . 4 . Willing able comply study requirement . 5 . Written informed consent . 1 . Invasive melanoma . 2 . Medical psychiatric condition compromise ability patient complete protocol treatment followup assessment . 3 . Patients pregnant lactate . Women child bear potential must confirm negative urine pregnancy test study entry . 4 . Life expectancy le 2 year . 5 . Radiotherapy sensitivity syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lentigo maligna</keyword>
	<keyword>Imiquimod</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>